SCHEMBL24575249

SCHEMBL24575249

CCOC(=O)CC(/C=C/c1ccccc1)CC(=O)OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
ALDH1A1 P00352 6/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
TSHR P16473 1/20 0.49
RAB9A P51151 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
NPC1 O15118 2/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KDM4E B2RXH2 4/20 0.46
HPGD P15428 3/20 0.46
ADORA3 P0DMS8 2/20 0.46
MAPT P10636 2/20 0.46
XBP1 P17861 1/20 0.46
POLB P06746 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
CYP1A2 P05177 1/20 0.44
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16865346 0.86 MEN1 (0.49) MEN1KMT2AALDH1A1CTDSP1TSHR
SCHEMBL16865347 0.86 MEN1 (0.49) MEN1KMT2AALDH1A1CTDSP1TSHR
SCHEMBL10764722 0.81 CYP4F2 (0.44) MEN1KMT2AALDH1A1CTDSP1TSHR
SCHEMBL11283691 0.81 CYP4F2 (0.44) MEN1KMT2AALDH1A1CTDSP1TSHR
SCHEMBL6067669 0.80 MEN1 (0.53) MEN1KMT2AALDH1A1CTDSP1TSHR
SCHEMBL29083692 0.79 PAM (0.52) ALDH1A1L3MBTL1NPC1LMNASMN1; SMN2
SCHEMBL28319517 0.79 MEN1 (0.51) MEN1KMT2AALDH1A1CTDSP1TSHR
SCHEMBL25159581 0.79 MEN1 (0.51) MEN1KMT2AALDH1A1CTDSP1TSHR
SCHEMBL23430575 0.79 TDP1 (0.38) MEN1KMT2AALDH1A1RAB9AL3MBTL1
SCHEMBL27978308 0.77 MEN1 (0.50) MEN1KMT2AALDH1A1CTDSP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145595-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 UNITED STATES GOVERNMENT 2025-05-08 US disclosed
CN-118541365-A Antagonists of muscarinic acetylcholine receptor M4 范德堡大学 2024-08-23 CN disclosed
US-20240228468-A1 N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS VANDERBILT UNIVERSITY 2024-07-11 US disclosed
US-20240174655-A1 INDAZOLE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2024-05-30 US disclosed
US-20240109873-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2024-04-04 US disclosed
WO-2022261427-A1 (4-(6-((2-OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)PHENYL)(IMINO)(METHYL)-LAMBDA6- SULFANONE DERIVATIVES AND SIMILAR COMPOUNDS AS MUSCARINIC ACETYLCHOLINE RECEPTOR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS VANDERBILT UNIVERSITY (US) 2022-12-15 WO disclosed
WO-2022216655-A1 N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS VANDERBILT UNIVERSITY (US) 2022-10-13 WO disclosed
WO-2022212819-A1 INDAZOLE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2022-10-06 WO disclosed
WO-2022212819-A1 INDAZOLE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2022-10-06 WO disclosed
WO-2022140499-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174655-A1 INDAZOLE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 CHRM3, CHRM5, CHRM2 MEN1 2489/4885KMT2A 2694/4885ALDH1A1 1434/4885
US-20240109873-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 CHRM3, CHRM2, CHRM4 MEN1 1463/4885KMT2A 2022/4885ALDH1A1 1543/4885
US-20240228468-A1 N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS CHRM5, CHRM1, CHRM2 MEN1 4685/4885KMT2A 424/4885ALDH1A1 1704/4885
US-20250145595-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 CHRM4, CHRM3, CHRM5 MEN1 2920/4885KMT2A 1593/4885ALDH1A1 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.